Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)

G. Hillas, P. Bakakos, P. Plantza, M. Kompoti, A. Rasidakis (Athens, Greece)

Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Session: Diagnostic markers and therapy in hospital-acquired pneumonia
Session type: Thematic Poster Session
Number: 2413
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Hillas, P. Bakakos, P. Plantza, M. Kompoti, A. Rasidakis (Athens, Greece). Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP). Eur Respir J 2007; 30: Suppl. 51, 2413

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007


C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005

Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP)
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016


C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012


C-reactive protein (CRP) at admission: is it really usefull in COVID-19 pneumonia?
Source: Virtual Congress 2021 – COVID - 19 biomarkers
Year: 2021


C-reactive protein (CRP), an early prognostic tool in community acquired pneumonia (CAP)
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009


Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP)
Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment
Year: 2013


High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010


C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia
Source: Eur Respir J 2010; 35: 805-811
Year: 2010



The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004

Diagnostic accuracy of lipopolysaccharide-binding protein (LBP), fibrinogen and C-reactive protein (CRP) in differentiating pneumonia from acute bronchitis in primary care
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006

Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia
Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention
Year: 2008


Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008


Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients
Source: Annual Congress 2012 - Respiratory infections: a clinical point of view
Year: 2012


C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018


Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia
Source: Eur Respir J 2008; 31: 356-362
Year: 2008



C-reactive protein (CRP) in the prognosis of complications of parapneumonic effusions (PPE)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010


Measurements usefulness of serum C-reactive protein for management of adult community-acquired pneumonia
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009